Endocrine Abstracts

Introduction: The stability of glycated hemoglobin (HbA1c) as a key to the prevention of micro-and macrovascular complications continues to be discussed.

Purpose: to analyze the interrelations between HbAc trajectories and clinical and biochemical parameters in patients with CHD and DM 2.

Material and methods: 130 patients with CAD and DM-2 aged 63.9±8.8 years. Therapy: DPP-4 inhibitors, GLP agonists. Groups: HbA1c <7.0 (n-27; A); 7.0<HbA1c<8.0 (n-25; B); HbA1c > 8.0 (n-78; C). 2 years of observation.

Results: In patients with unchanged HbA1c, there is an increase in vitamin D: with HbA1c<8, n-47 Δ 6.54 ng/ml, P=0.003; HbA1c>8.1, n-50 Δ 8.24 ng/ml, P=0.004. CRP and BNP in dynamics: HbA1c<8, n-47 Δ 4.18 ng/ml, P=0.002 and Δ 363.0 pg/ml, P=0.01, respectively. HbA1c > 8.1 CRP and BNP n-50 Δ 2.75 ng/ml, P=0.02 and Δ 432.2 pg/ml, P=0.02. A high content of UA is recorded in group C and C´ (with HbA1c > 8.1) (P=0.02). With HbA1c<8, there is a decrease in vitamin D 16.65[10.00-22.50] and a high BNP 2052.78 [1247.50-2977.50] pg/ml. A direct correlation was established between PPG and the metabolic index (r=0.367; P=0.009); vitamin D and BNP (r=0.336; P=0.017) and vitamin D with eGFR (r=0.429; P=0.002) in group C (HbA1c remained >8.1).

Conclusion: A two-year follow-up of HbA1c showed that alternating target values were recorded. Correlations of vitamin D in the blood (both deficiency and insufficiency) with high BNP in patients with HbA1>8.1 were revealed, which confirms the role of vitamin D in the progression of heart failure and renal dysfunction.